2041-LB: Continuous Protein Sensor for Sarcopenia Management during GLP-1RA Therapy

Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective in both weight loss and glycemic control for people with Obesity and/or Diabetes but can result in sarcopenia - loss of lean muscle mass (LLMM) (1). LLMM effects (2) can be overcome through exercise and increased protein consumption. Phenylalanine (phe) is an essential amino acid released from skeletal muscle breakdown and exogenous protein ingestion. A wearable phenylalanine sensor with activity monitor could track LLMM and protein ingestion for use with these transformative medications. This sensor utilizes a new methodology that relies on an engineered phe bioreceptor using a short nucleic acid sequence (aptamer) labeled with a methylene blue redox probe. This aptamer is attached to an electrode surface where the binding and concentration of the phe is measured through the electrochemical technique square wave voltammetry. Methods: The aptamer bioreceptor was applied to microneedle electrodes and a calibration (0-1500 µM/L) was performed in phosphate buffer solution (PBS). Results: The phe sensor showed log-linear calibration on day 1 and 7 (Fig 1), R^2 d1: 0.986, d7: 0.994, with low limit of detection d1: 3.9 µM/L, d7: 6.4 µM/L. Conclusion: This work demonstrated performance of a proof-of-concept continuous protein monitor utilizing an engineered bioreceptor on a microsensor array that could be used in conjunction with GLP-1 RA therapy. Disclosure R. Gottlieb: Employee; Biolinq. B. Wang: Employee; Biolinq. J.E. Kavner: Employee; Biolinq. K. Mallires: Employee; Biolinq. J.R. Tangney: None.